novotech Webinars

  1. Implementing A Diversity Plan For Your Clinical Trial 12/5/2024

    Industry leaders dive into the FDA’s Diversity Action Plans and practical strategies for integrating diversity action plans into clinical trial operations in a presentation centered around enhancing trial diversity.

  2. Adapting Clinical Strategies For Rapid Response 12/5/2024

    This presentation aims to equip sponsors, researchers, and stakeholders with the tools to enhance trial resilience and ensure continuity in today’s unpredictable global landscape.

  3. Accelerating Development In Novel & Advanced Oncology Therapies 6/15/2023

    Hear from a panel of industry experts on dissecting the shift in early-phase oncology design, focusing on Bayesian Data.

  4. Keeping Pace With The Evolving Global Landscape In Vaccine Development 5/9/2023

    Hear from a panel of life science experts about the most recent developments and ground-breaking approaches shaping the field of vaccine development worldwide.

  5. The Biotech Landscape: Market Trends, Priorities, Predictions, And Pathways To FDA Approval 10/27/2022

    The webinar features regulatory affairs and investment leaders from North America and Asia Pacific who will discuss why biotech companies are increasingly exploring clinical opportunities in Asia Pacific to generate diverse, globally accepted clinical trial data, and much more.

  6. Go/No Go Decisions Based On Early Phase Oncology Trials 9/22/2022

    In this webinar, gain insight into the latest regulatory and clinical developments in the field of oncology in China.

  7. Development And Regulatory Strategy For US And China 9/22/2022

    This webinar discusses the expansion of International Market for Ensartini and RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers.

  8. Accelerating Clinical Development In China & The US 9/22/2022

    Discover how the clinical research bridge between China and the US supports accelerated clinical development from early to late phase trials while ensuring the inclusion of MRCT data packages in future regulatory applications.

  9. Evolution Of Cell & Gene Therapy In China: The Case For Universal CAR-T 9/22/2022

    China now represents 60% of clinical development in CAR-T therapy development globally: what have we learned to date and where are future opportunities?